-
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial Eur. Urol. (IF 25.3) Pub Date : 2024-06-18 Ruben Raychaudhuri, Makayla DeJong, Matthew Rettig, Evan Y. Yu, Roman Gulati, Michael T. Schweizer, Peter S. Nelson, Colin C. Pritchard, Bruce Montgomery, Heather H. Cheng
-
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, Santiago Gonzalez, Maja Kuzman, Jurica Levatic, Dunja Glavas, Ryan Ptashkin, James Smadbeck, Danielle Afterman, Tomer Lauterman, Yarin Cohen, Zohar Donenhirsh, Iman Tavassoly, Ury Alon, Amanda Frydendahl, Mads Heilskov Rasmussen, Claus Lindbjerg Andersen, Philippe Lamy, Michael Knudsen, Paz Polak, Asaf Zviran, Boris Oklander, Mads Agerbæk
Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in settings of low tumor burden is limited by the number of mutations analyzed and the plasma volume available. We used a whole-genome sequencing (WGS) approach for ctDNA detection in patients with urothelial carcinoma. We used a tumor-informed WGS approach
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Primo N. Lara Jr, Catherine Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell Meng, Ajjai Shivaram Alva, Sumanta K. Pal, Igor Puzanov, Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Seth Lerner, Ian M. Thompson Jr, Christopher W. Ryan
EVEREST is a phase 3 trial in patients with renal cell cancer (RCC) at intermediate-high or very high risk of recurrence after nephrectomy who were randomized to receive adjuvant everolimus or placebo. Longer recurrence-free survival (RFS) was observed with everolimus (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.72–1.00; = 0.051), but the nominal significance level ( = 0.044) was not reached
-
Challenging the Urologist of the Future: Time for a Change? Eur. Urol. (IF 25.3) Pub Date : 2024-05-29 Fabian P. Stangl, Isabel Heidegger, Pia Kraft, Rianne J.M. Lammers, Mark Horvath, Muslim Dogan Deger, Elvira Polo-Alonso, Mike Wenzel, Andres Affentranger, Katrine Schou-Jensen, Lobna Ali, Robert A. Keenan, Anna Cadenar, Laura Gallardo-Zamora, Josias Franco Alva, Domenico Trerè, Georgios Tsampoukas, Peter Hoyerup, Clara Cerrato, Nicolas Raison, Sabine Brookman-May, Juan Luis Vásquez
-
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe Eur. Urol. (IF 25.3) Pub Date : 2024-05-23 Pieter Vynckier, Lieven Annemans, Sarah Raes, Cheïma Amrouch, Peter Lindgren, Ondřej Májek, Katharina Beyer, Renée C.A. Leenen, Lionne D.F. Venderbos, Frederique Denijs, Meike J. van Harten, Jozien Helleman, Renata Chloupková, Erik Briers, Vera Vasilyeva, Juan Gomez Rivas, Partha Basu, Arunah Chandran, Roderick C.N. van den Bergh, Sarah Collen, Hein Van Poppel, Monique J. Roobol, Members of the PRAISE-U
In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes. A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases
-
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review Eur. Urol. (IF 25.3) Pub Date : 2024-05-22 Adam B. Weiner, Preeti Kakani, Andrew J. Armstrong, Alberto Bossi, Philip Cornford, Felix Feng, Pratik Kanabur, R. Jeffery Karnes, Rana R. Mckay, Todd M. Morgan, Edward M. Schaeffer, Neal Shore, Alison C. Tree, Daniel E. Spratt
Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy
-
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials Eur. Urol. (IF 25.3) Pub Date : 2024-05-22 Praful Ravi, Wanling Xie, Marc Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Gert Attard, Noel Clarke, Anthony D'Amico, James Dignam, Nicholas James, Karim Fizazi, Silke Gillessen, Wendy Parulekar, Howard Sandler, Daniel E. Spratt, Matthew R. Sydes, Bertrand Tombal, Scott Williams, Christopher J. Sweeney
Radiotherapy (RT) and long-term androgen deprivation therapy (ltADT; 18–36 mo) is a standard of care in the treatment of high-risk localized/locoregional prostate cancer (HRLPC). We evaluated the outcomes in patients treated with RT + ltADT to identify which patients have poorer prognosis with standard therapy. Individual patient data from patients with HRLPC (as defined by any of the following three
-
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-20 Andreas Josefsson, Marianne Månsson, Kimia Kohestani, Vasiliki Spyratou, Jonas Wallström, Mikael Hellström, Hans Lilja, Andrew Vickers, Sigrid V. Carlsson, Rebecka Godtman, Jonas Hugosson
We investigated whether adding 4Kscore as a reflex test to prostate-specific antigen (PSA) could improve the screening algorithm for prostate cancer (PC). In the GÖTEBORG-2 PC screening trial, 38 000men (50–60 yr) were invited to PSA testing and, if elevated, followed by magnetic resonance imaging (MRI). For 571 men with PSA ≥3.0 ng/ml and evaluable outcomes, 4Kscore was calculated. The performance
-
Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort Eur. Urol. (IF 25.3) Pub Date : 2024-05-16 Christian D. Fankhauser, Marian S. Wettstein, Christoph Würnschimmel, Maarten van Smeden, Noel W. Clarke
-
Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial Eur. Urol. (IF 25.3) Pub Date : 2024-05-15 Agne Krilaviciute, Rudolf Kaaks, Petra Seibold, Maxime de Vrieze, Jale Lakes, Jan Philipp Radtke, Markus Kuczyk, Nina N. Harke, Jürgen Debus, Christoph A. Fink, Kathleen Herkommer, Jürgen E. Gschwend, Valentin H. Meissner, Axel Benner, Glen Kristiansen, Boris Hadaschik, Christian Arsov, Lars Schimmöller, Gerald Antoch, Frederik L. Giesel, Marcus Makowski, Frank Wacker, Heinz-Peter Schlemmer, Nikolaus
Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55–60 yr. To identify men at age 45 yr with a low risk of PCa. A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen
-
Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review Eur. Urol. (IF 25.3) Pub Date : 2024-05-14 Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, Marcus J. Drake, Christian Gratzke, Benoit Peyronnet, Claus Roehrborn, Kari A.O. Tikkinen, Jean-Nicolas Cornu, Ferdinando Fusco
Symptomatic benefit and urodynamic obstruction relief represent relevant outcomes of therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). We summarized evidence from studies concurrently assessing variations in terms of symptoms severity and invasive urodynamic measures of obstruction following medical and surgical therapies for LUTS/BPH. We performed a
-
European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines Eur. Urol. (IF 25.3) Pub Date : 2024-05-06 Jennifer Kranz, Riccardo Bartoletti, Franck Bruyère, Tommaso Cai, Suzanne Geerlings, Bela Köves, Sören Schubert, Adrian Pilatz, Rajan Veeratterapillay, Florian M E Wagenlehner, Kathrin Bausch, Wout Devlies, József Horváth, Lorenz Leitner, Guglielmo Mantica, Tunde Mezei, Emma J. Smith, Gernot Bonkat
Urological infections significantly impact the wellbeing and quality of life of individuals owing to their widespread occurrence and diverse clinical manifestations. The objective of the guidelines panel was to provide evidence-based guidance on the diagnosis, treatment, and prevention of urinary tract infections (UTIs) and male accessory-gland infections, while addressing crucial public health aspects
-
Reply to Ilias Giannakodimos’ Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68 Eur. Urol. (IF 25.3) Pub Date : 2024-04-26 Jim C. Hu, Edward M. Schaeffer, Andrew J. Vickers
-
Reply to Geoffrey H. Rosen, Nicholas H. Chakiryan, and Katie S. Murray’s Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68 Eur. Urol. (IF 25.3) Pub Date : 2024-04-26 Jim C. Hu, Andrew J. Vickers, Edward M. Schaeffer
-
Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies. Eur Urol. In press Eur. Urol. (IF 25.3) Pub Date : 2024-04-26 Jim C. Hu, Andrew J. Vickers, Edward M. Schaeffer
-
Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy Eur. Urol. (IF 25.3) Pub Date : 2024-04-26 Deep Chakrabarti, Chris C. Parker
-
Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization Eur. Urol. (IF 25.3) Pub Date : 2024-04-26 Laura Elst, Gino Philips, Kaat Vandermaesen, Ayse Bassez, Francesca Lodi, Manon T.A. Vreeburg, Oscar R. Brouwer, Rogier Schepers, Thomas Van Brussel, Sambit K. Mohanty, Anil V. Parwani, Lien Spans, Isabelle Vanden Bempt, Gerd Jacomen, Marcella Baldewijns, Diether Lambrechts, Maarten Albersen
loss-of-function (TP53LOF) mutations might be a driver of poor prognosis and chemoresistance in both human papillomavirus (HPV)-independent (HPV–) and HPV-associated (HPV+) penile squamous cell carcinoma (PSCC). Here, we aim to describe transcriptomic differences in the PSCC microenvironment stratified by TP53LOF and HPV status. We used single-cell RNA sequencing (scRNA-seq) and T-cell receptor sequencing
-
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68 Eur. Urol. (IF 25.3) Pub Date : 2024-04-24 Geoffrey H. Rosen, Nicholas H. Chakiryan, Katie S. Murray
-
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol 2024;85:146–53 Eur. Urol. (IF 25.3) Pub Date : 2024-04-21 José David Cardona Ortegón, Samuel Serrano, Daniel Romero Cortes
-
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68 Eur. Urol. (IF 25.3) Pub Date : 2024-04-21 Ilias Giannakodimos
-
Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105–11 Eur. Urol. (IF 25.3) Pub Date : 2024-04-21 José D. Cardona Ortegón, Laura A. Campaña Perilla, Laura M. Olarte Bermúdez
-
Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies Eur. Urol. (IF 25.3) Pub Date : 2024-04-21 Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party
-
Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024;85:217–226 Eur. Urol. (IF 25.3) Pub Date : 2024-04-21 Elif Hindié, Christophe Champion, Clément Morgat
-
Orthotopic Robot-assisted Kidney Transplantation: Surgical Technique and Preliminary Results Eur. Urol. (IF 25.3) Pub Date : 2024-04-15 Francesc Vigués, Begoña Etcheverry, José I. Perez Reggeti, Josep Maria Gaya, Angelo Territo, Andrea Gallioli, Camille Berquin, Giuseppe Basile, José F. Suárez, Maria Fiol, Oscar Buisan, Lluís Riera, Thomas Prudhomme, Nicolas Doumerc, Alessio Pecoraro, Alberto Breda, European Association of Urology Robotic Urology Section Robot-assisted Kidney Transplantation Working Group
Orthotopic kidney transplantation (KT) has been proposed as an option for patients ineligible for heterotopic KT. In this scenario, orthotopic robot-assisted KT (oRAKT) represents a novel, minimally invasive alternative to the open approach. Here we describe the largest oRAKT series of patients, with a focus on the surgical technique, perioperative surgical outcomes, and functional results. We queried
-
Re: Multi-omic Profiling of Clear Cell Renal Cell Carcinoma Identifies Metabolic Reprogramming Associated with Disease Progression Eur. Urol. (IF 25.3) Pub Date : 2024-04-12 Aimin Jiang, Le Qu, Chen Cai, Peng Luo, Linhui Wang
-
Summary of the 2024 Update of the European Association of Urology Guidelines on Neuro-urology Eur. Urol. (IF 25.3) Pub Date : 2024-04-08 Andrea M. Sartori, Thomas M. Kessler, David M. Castro-Díaz, Peter de Keijzer, Giulio Del Popolo, Hazel Ecclestone, Dennis Frings, Jan Groen, Rizwan Hamid, Gilles Karsenty, Stefania Musco, Bárbara Padilla-Fernández, Jürgen Pannek, Natasha Schouten, Angela van der Vorm, Bertil F.M. Blok
Most patients with neurourological disorders require lifelong medical care. The European Association of Urology (EAU) regularly updates guidelines for diagnosis and treatment of these patients. The objective of this review is to provide a summary of the 2024 updated EAU guidelines on neurourology. A structured literature review covering the timeframe 2021–2023 was conducted for the guideline update
-
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study Eur. Urol. (IF 25.3) Pub Date : 2024-04-06 Robert J. Motzer, Toni K. Choueiri, Thomas Hutson, Sun Young Rha, Javier Puente, Aly-Khan A. Lalani, Eric Winquist, Masatoshi Eto, Naveen S. Basappa, Nizar M. Tannir, Ulka Vaishampayan, Georg A. Bjarnason, Stéphane Oudard, Viktor Grünwald, Joseph Burgents, Ran Xie, Jodi McKenzie, Thomas Powles
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall
-
Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579–87 Eur. Urol. (IF 25.3) Pub Date : 2024-04-06 Hannah L. Rush, Duncan C. Gilbert, Ruth E. Langley
-
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis Eur. Urol. (IF 25.3) Pub Date : 2024-04-03 Soumyajit Roy, Gagan Fervaha, Daniel E. Spratt, Yilun Sun, Amar U. Kishan, Andrew Loblaw, Shawn Malone, Michael Ong, Fred Saad, Christopher J.D. Wallis, Scott C. Morgan
The utility of prostate radiotherapy (RT) is unclear in men with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic therapy with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs). We performed a network meta-analysis of randomized controlled trials (RCTs) to investigate the role of prostate RT in low-volume mHSPC. Bibliographic databases
-
Re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol 2024;85:63–71 Eur. Urol. (IF 25.3) Pub Date : 2024-04-03 Angela Estevez, Phillip Kim, Peter Chang, Andrew A. Wagner
-
Reply to Angela Estevez, Phillip Kim, Peter Chang, and Andrew A. Wagner’s Letter to the Editor re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. Eur Urol 2024;85:63–71 Eur. Urol. (IF 25.3) Pub Date : 2024-04-03 Giuseppe Basile, Alessandro Larcher, Arturo Chiti, Alberto Breda, Umberto Capitanio
-
Thulium Fiber Laser Versus Holmium:Yttrium Aluminum Garnet for Lithotripsy: Which Is the Winner? Eur. Urol. (IF 25.3) Pub Date : 2024-04-03 Olivier Traxer, Margaret Pearle
-
PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-03-30 Cameron Englman, Davide Maffei, Clare Allen, Alex Kirkham, Peter Albertsen, Veeru Kasivisvanathan, Ronaldo Hueb Baroni, Alberto Briganti, Pieter De Visschere, Louise Dickinson, Juan Gómez Rivas, Masoom A. Haider, Claudia Kesch, Stacy Loeb, Katarzyna J. Macura, Daniel Margolis, Anita M. Mitra, Anwar R. Padhani, Valeria Panebianco, Peter A. Pinto, Guillaume Ploussard, Philippe Puech, Andrei S. Purysko
The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting of prostate magnetic resonance imaging (MRI) in patients on active surveillance (AS) for prostate cancer. An international consensus group recently updated these recommendations and identified the areas of uncertainty. A panel of 38 experts used the formal RAND/UCLA Appropriateness
-
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? Eur. Urol. (IF 25.3) Pub Date : 2024-03-27 Alessia Cimadamore, Gianluca Giannarini, Alessandro Crestani, Antonio Lopez-Beltran, Rodolfo Montironi, Liang Cheng
-
Re: Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-03-26 Alice Bourillon, Karim Bensalah
-
Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience Eur. Urol. (IF 25.3) Pub Date : 2024-03-26 Olivier Windisch, Massimo Valerio
-
Re: Erdafitinib in BCG-treated High-risk Non–muscle-invasive Bladder Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-03-26 Igor Duquesne, Alexandre de la Taille
-
Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo’s Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3–7 Eur. Urol. (IF 25.3) Pub Date : 2024-03-26 Christopher J. Logothetis, Andrew W. Hahn
-
Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3–7 Eur. Urol. (IF 25.3) Pub Date : 2024-03-26 Richard J. Wassersug, Paul F. Schellhammer, Erik Wibowo
-
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-03-26 Constantin Tilgener, Jens Bedke
-
Re: Autologous Platelet Rich Plasma (A-PRP) Combined with Pelvic Floor Muscle Training for the Treatment of Female Stress Urinary Incontinence (SUI): A Randomized Control Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-03-25 Andrea Braga, Andrea Papadia, Maurizio Serati
-
Re: Laparoscopic Sacrocolpopexy Versus Vaginal Sacrospinous Fixation for Vaginal Vault Prolapse: A Randomised Controlled Trial and Prospective Cohort (SALTO-2 Trial) Eur. Urol. (IF 25.3) Pub Date : 2024-03-25 Andrea Braga, Andrea Papadia, Maurizio Serati
-
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015 Eur. Urol. (IF 25.3) Pub Date : 2024-03-25 Giancarlo Marra, Marco Oderda, Paolo Gontero, Collaborator, Lorenzo Richiardi
-
Re: Roxana Ramos, Ethan Ferguson, Mahmoud Abou Zeinab, et al. Single-port Transvesical Robot-Assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes. Eur Urol. 2024;85:445–456 Eur. Urol. (IF 25.3) Pub Date : 2024-03-23 Alessandro Guercio, Antonio Franco, Elisa Mancini, Riccardo Lombardo, Francesco Curto, Giorgio Franco, Cosimo De Nunzio
-
Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-03-23 Yuzhen Zhou, Vincent D. D'Andrea, Surish P. Shanmugam, Isabella Stelter, Dag R. Stormoen, Rea Chroneos, Timothy Hanlon, Ilana Epstein, Raie T. Bekele, William J. Anderson, Filipe F.L. Carvalho, Joaquim Bellmunt, Kent W. Mouw
-
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study Eur. Urol. (IF 25.3) Pub Date : 2024-03-22 Roberto Iacovelli, Chiara Ciccarese, Sebastiano Buti, Paolo Andrea Zucali, Emanuela Fantinel, Davide Bimbatti, Elena Verzoni, Caterina Accettura, Lucia Bonomi, Consuelo Buttigliero, Giuseppe Fornarini, Stefania Pipitone, Francesco Atzori, Cristina Masini, Francesco Massari, Francesca Primi, Alessandro Strusi, Giulia Claire Giudice, Matteo Perrino, Marco Maruzzo, Michele Milella, Diana Giannarelli,
Combinations of VEGFR-TKIs plus ICI against PD1/PD-L1 are the standard first-line therapy for patients with mRCC, irrespective of the prognostic class. This study aims to investigate the feasibility and safety of withdrawing the VEGFR-TKI but continuing the anti- PD1/PD-L1 in patients who achieve response to their combination. This was a single-arm phase 2 trial in patients with treatment naïve mRCC
-
Reply to Alessandro Guercio, Antonio Franco, Elisa Mancini, et al’s Letter to the Editor re: Roxana Ramos, Ethan Ferguson, Mahmoud Abou Zeinab, et al. Single-port Transvesical Robot-assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes. Eur Urol. 2024;85:445–456 Eur. Urol. (IF 25.3) Pub Date : 2024-03-22 Roxana Ramos, Jihad Kaouk
-
Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not Eur. Urol. (IF 25.3) Pub Date : 2024-03-22 Gert De Meerleer, Steven Joniau, Jan Benijts, Kato Rans
-
Re: BilR is a Gut Microbial Enzyme that Reduces Bilirubin to Urobilinogen Eur. Urol. (IF 25.3) Pub Date : 2024-03-22 Prokar Dasgupta
-
Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen–targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy Eur. Urol. (IF 25.3) Pub Date : 2024-03-22 Maximilian Burger
-
The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations Eur. Urol. (IF 25.3) Pub Date : 2024-03-21 Alexander Light, Nikhil Mayor, Emma Cullen, Alex Kirkham, Anwar R. Padhani, Manit Arya, Joyce G.R. Bomers, Tim Dudderidge, Behfar Ehdaie, Alex Freeman, Stephanie Guillaumier, Richard Hindley, Amish Lakhani, Douglas Pendse, Shonit Punwani, Ardeshir R. Rastinehad, Olivier Rouvière, Rafael Sanchez-Salas, Ivo G. Schoots, Heminder K. Sokhi, Henry Tam, Clare M. Tempany, Massimo Valerio, Sadhna Verma, Geert
Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce consensus recommendations on MRI acquisition, interpretation, and reporting after focal therapy. A systematic review was performed in July 2022 to develop consensus statements. A two-round consensus exercise was then performed
-
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur. Urol. (IF 25.3) Pub Date : 2024-03-16 Michael Baboudjian, Romain Diamand, Alessandro Uleri, Jean-Baptiste Beauval, Alae Touzani, Jean-Baptiste Roche, Vito Lacetera, Thierry Roumeguère, Giuseppe Simone, Daniel Benamran, Alexandre Fourcade, Bastien Gondran-Tellier, Gaelle Fiard, Alexandre Peltier, Guillaume Ploussard
Targeted biopsy of the index prostate cancer (PCa) lesion on multiparametric magnetic resonance imaging (MRI) is effective in reducing the risk of overdiagnosis of indolent PCa. However, it remains to be determined whether MRI-targeted biopsy can lead to a stage shift via overgrading of the index lesion by focusing only on the highest-grade component, and to a subsequent risk of overtreatment. Our
-
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-03-16 John Nikitas, Matthew Rettig, John Shen, Robert Reiter, Alan Lee, Michael L. Steinberg, Luca F. Valle, Ankush Sachdeva, Tahmineh Romero, Jeremie Calais, Johannes Czernin, Nicholas G. Nickols, Amar U. Kishan
Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6 mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence
-
Corrigendum to “European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines” [Eur. Urol. 85 (2024) 17–31] Eur. Urol. (IF 25.3) Pub Date : 2024-03-15 J. Alfred Witjes, Harman Max Bruins, Albert Carrión, Richard Cathomas, Eva Compérat, Jason A. Efstathiou, Rainer Fietkau, Georgios Gakis, Anja Lorch, Alberto Martini, Laura S. Mertens, Richard P. Meijer, Matthew I. Milowsky, Yann Neuzillet, Valeria Panebiaco, John Redlef, Michael Rink, Mathieu Rouanne, George N. Thalmann, Sæbjørn Sæbjørnsen, Erik Veskimäe, Paramananthan Mariappan, Antoine G. van der
-
Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.09.024 Eur. Urol. (IF 25.3) Pub Date : 2024-03-15 Olivier Cussenot, Antoine Chambaz, Freddie C. Hamdy
-
Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study Eur. Urol. (IF 25.3) Pub Date : 2024-03-15 Manuel Weber, Wolfgang P. Fendler, Aravind S. Ravi Kumar, Jeremie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Alexander Kretschmer, Turkay Hekimsoy, Sabine D. Brookman-May, Suneel D. Mundle, Eric J. Small, Matthew R. Smith, Paola M. Perez, Thomas A. Hope, Ken Herrmann, Michael S. Hofman, Matthias Eiber, Boris A. Hadaschik
Previously, we demonstrated that prostate-specific membrane antigen positron emission tomography (PSMA-PET) revealed distant metastases in 109/200 patients (39% distant nodes, 24% bone, and 6% visceral organ) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and high-risk features (International Society of Urological Pathology score ≥4 and/or prostate-specific antigen doubling time ≤10 mo)
-
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population Eur. Urol. (IF 25.3) Pub Date : 2024-03-14 Rodolfo Montironi, Alessia Cimadamore, Gianluca Giannarini, Alessandro Crestani, Antonio Lopez-Beltran, Liang Cheng
-
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-03-14 Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, Rafael Morales-Barrera, Francesco Grussu, Irene Casanova-Salas, Francesco Sanguedolce, Macarena Gonzalez, Pablo Cresta-Morgado, Matias de Albert, Josep Garcia-Bennett, David Marmolejo, Jacques Planas, Sarai Roche, Richard Mast, Christina Zatse, Josep M Piulats, Bernardo Herrera-Imbroda, Lucas Regis, Laura Agundez, David Olmos, Nahum Calvo, Manuel
-
Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07) Eur. Urol. (IF 25.3) Pub Date : 2024-03-14 Loig Vaugier, Cyrille Morvan, David Pasquier, Xavier Buthaud, Nicolas Magné, Veronique Beckendorf, Paul Sargos, Gilles Crehange, Pascal Pommier, Genevieve Loos, Ali Hasbini, Igor Latorzeff, Marlon Silva, Julie Paul, Audrey Blanc-Lapierre, Stéphane Supiot
Androgen deprivation therapy (ADT) is a mainstay in metastatic prostate cancer, while additional salvage radiotherapy may offer prolonged remission for patients with regional node relapses. We performed an open-label, phase II trial to assess the long-term outcomes and patterns of relapse of 6-months ADT and elective pelvic radiotherapy in men with oligorecurrent (<6) pelvic nodes in prostate cancer
-
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-03-14 Nicholas G. Nickols, Sonny Tsai, Nathanael Kane, Samantha Tran, Leila Ghayouri, Silvia Diaz-Perez, May Thein, Nancy Anderson-Berman, Jeanie Eason, Amar U. Kishan, Michael L. Steinberg, Robert E. Reiter, Steve P. Lee, Greg E. Gin, Robert Kwon, Michael G. Chang, Hann-Hsiang Chao, Abhiskek A. Solanki, Rachael Sexton, Michael Lewis, William Lorentz, Michael K. Cheung, Diana L. Gage, Sai Duriseti, Luca